Zobrazeno 1 - 10
of 36
pro vyhledávání: '"James E. Gottesman"'
Autor:
Steven J. Rosenberg, Howard R. Goldstein, Ghulam Warsi, Gerald W. Hull, James E. Gottesman, Ron S. Israeli, Leo V. Lacerna, Daniel Saltzstein, Diep Tran
Publikováno v:
Clinical Genitourinary Cancer. 5:271-277
The aim of this study was to evaluate the efficacy and safety of zoledronic acid compared with placebo in preventing bone mineral density (BMD) loss and suppressing bone markers when initiated during the first year of androgen deprivation therapy in
Autor:
James E. Gottesman, Michael F. Sarosdy, H. Barton Grossman, E. David Crawford, Thomas M. Beck, Donald L. Lamm, John D. Crissman, Joseph T. Leimert, Brent A. Blumenstein, James E. Montie, Robert D. Bohl, Bruce A. Lowe
Publikováno v:
The Journal of Urology. :1124-1129
Purpose:: Bacillus Calmette-Guerin (BCG) immunotherapy has been widely accepted as the optimal treatment for carcinoma in situ and high grade superficial transitional cell carcinoma. However, controversy remains regarding the role of maintenance ther
Autor:
John Bannow, Jonathan I. Epstein, Kerry Short, Paul F. Schellhammer, Raul O. Parra, G.Byron Hodge, Stephen Rouse, Joanne Waldstreicher, William P. Fitch, Lloyd J. Peterson, Ximing J. Yang, James E. Gottesman, Kristen Lecksell
Publikováno v:
Urology. 53:696-700
Objectives. Finasteride, a common agent used to treat benign prostatic hyperplasia (BPH), inhibits 5-alpha-reductase. Testosterone is converted by 5-alpha-reductase to the more potent dihydrotestosterone, which is the primary androgen in the prostate
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 41:525-533
Background: Results from localized prostate cancer series using seed implants have been most encouraging. However, with current techniques, inadequate dosimetry sometimes occurs. Remote afterloading high dose rate 192Iridium brachytherapy (HDR-Ir192)
Autor:
Seon-Joo, Yoon, Seung-Yeol, Park, Poh-Choo, Pang, Jenni, Gallagher, James E, Gottesman, Anne, Dell, Jung-Hoe, Kim, Sen-Itiroh, Hakomori
Publikováno v:
International journal of oncology. 36(1)
N-glycosylation status of purified beta-haptoglobin separated from sera of patients with prostate cancer was studied in comparison to that of sera from patients with benign prostate diseases, or normal subjects. Two different approaches, as summarize
Autor:
Seung-Yeol Park, James E. Gottesman, Jung Hoe Kim, Poh-Choo Pang, Seon-Joo Yoon, Sen-itiroh Hakomori, Anne Dell, Jenni Gallagher
N-glycosylation status of purified beta-haptoglobin separated from sera of patients with prostate cancer was studied in comparison to that of sera from patients with benign prostate diseases, or normal subjects. Two different approaches, as summarize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b88aa66cabe3c83c4b2d9539d98c42
http://hdl.handle.net/10044/1/49847
http://hdl.handle.net/10044/1/49847
Autor:
James E, Gottesman
Publikováno v:
Journal of healthcare information management : JHIM. 19(4)
Autor:
Jennifer Drisko, Marc Gittelman, J. Curtis Nickel, Brian Saltzman, Alan G. Meehan, Joanne Waldstreicher, Reginald Bruskewitz, James E. Gottesman, Shilaja Suryawanshi, Gholem H. Malek, Claus G. Roehrborn, John D. McConnell
Publikováno v:
The Journal of urology. 171(3)
We determined the effect of long-term treatment with finasteride on the incidence of acute urinary retention (AUR) and benign prostatic hyperplasia (BPH) related surgery in men with BPH.The Proscar (Merck and Co., Inc., Whitehouse Station, New Jersey
Autor:
Andrzej Borkowski, Gerald L. Andriole, Harin Padma-Nathan, Charles B. Herring, Craig F. Donatucci, Vincenzo Gentile, A. Leriche, Eric Wespes, Jack Barkin, Randall P. Abele, Donald Bergner, H. Asscheman, Stacy Childs, William B. Monnig, Jon Lee Peterson, William A. Leitner, Arnold Melman, Fabrizio Menchini Fabris, R. F. Kropman, Enrico Pisani, Jack Lubensky, David Ralph, Stephen Auerbach, Jeoffrey Deeths, Nizamuddin Maruf, Fred Govier, Robert Feldman, Vincenzo Bonifacio, Roger De Bruyne, James E. Gottesman, F. Francesca, William Iii Fitch, Selwyn Cohen, Roger Fincher, Francis Duyck, Phillip Kell, Alan Lau, Björn Lundquist, Vincenzo Mirone, Emanuele Belgrano, Kazimierz Krajka, Evan R. Goldfischer, Francesco Paolo Selvaggi, Wilbert Dinsmore, Gaetano Frajese, Joel M. Kaufman, Pamela I. Ellsworth, V. Gary Price, Joel Lilly, Peter J. Pommerville, Geoffrey Hackett, M. Speakman, Wayne J.G. Hellstrom, Michael B. Greenspan, Pierre Bondil, Larry I. Gilderman, Emmanuel Blanc, Overlæge Peter Lyngdorf, Arcangelo Pagliarulo, Howard B. Epstein, Thierry Lebret, Thomas Gerstenberg, Keith Matthews, John N. Krieger, Peter Ekman, François Giuliano, Ian Eardley, Benny Verheyden, Roger Kirby, Allan B. Patrick, Georges Declercq, Jenelle E. Foote, Christer Dahlstrand, Eric J.H. Meuleman, Craig Niederberger, Mostafa M. Elhilali, Olivier Lan, Harold A. Fuselier, Andrew McCullough, Richard Casey, Winston Barzell, Beatrice Cuzin, Marc Gittelman, Kevin T. McVary, Louis Fields, Pierre Costa, Kanaiyalal Desai, Dirk Vanderscheuren, Robert J. Krane, Gary S. Karlin, Martin Homering, Francesco Montorsi, Giorgio Carmignani, Guglielmo Breda, Thom Segerson, Jacques Buvat, Robert Porto, David O. Cook, Jeffrey Frankel
Vardenafil (Levitra) is a potent and selective phosphodiesterase 5 (PDE5) inhibitor used in the management of erectile dysfunction (ED). This retrospective subgroup analysis assessed the effectiveness of vardenafil treatment in men with ED of differe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e89ba4cd8369d684bf7e2dfb20eb1a0
http://hdl.handle.net/11588/486018
http://hdl.handle.net/11588/486018
Publikováno v:
The Journal of urology. 164(3 Pt 1)
We evaluated the pharmacokinetics, safety and efficacy of the implantable Viadur++ leuprolide delivery system during 12 months in patients with advanced prostate cancer.Our open label, multicenter, dose ranging study was done in 2 phases. The treatme